How the American Cancer Society Fights Colon Cancer
In March, the Society launched a new initiative to increase nationwide colorectal screening rates from 65% to 80% by the year 2018. The initiative rallied individuals, communities, and systems to promote colorectal screening among all recommended populations. We believe this goal is achievable, but we can’t do it alone. Building on our strength convene critical partners to rally behind a shared nationwide goal, the American Cancer Society and the Centers for Disease Control and Prevention (CDC), along with the National Colorectal Roundtable – established in 1997 by the American Cancer Society and the CDC – will capitalize on National Colorectal Cancer Awareness Month to mobilize communities across the country and begin a national dialogue on how to achieve the 80% by 2018 goal.
Colorectal cancer (commonly called colon cancer) is the third most common cancer in both men and women in the United States, and the third leading cause of cancer death. But the death rate from this disease has been dropping thanks to improvements in colon cancer prevention, early detection, and treatment. Screening tests are available that can actually stop colon cancer before it starts, or catch it early, when treatments are more likely to be successful. Treatments have also improved over the years.
The American Cancer Society is actively fighting colon cancer on many fronts. We are helping people get tested for colon cancer, and helping them understand their diagnosis and get the treatments they need. The American Cancer Society also funds new research to help prevent, find, and treat colon cancer.
The most important thing you can do to prevent colon cancer is to get tested, and to encourage your employees to get tested as well. If you are age 50 or older, talk to your doctor about which test is right for you. Please talk to your Society staff partner about how you can educate your employees on the importance of colon cancer screening today.
Together, we can prevent and beat colon cancer.